Journal of Clinical Endocrinology & Metabolism, Vol 79, 1410-1415, Copyright © 1994 by Endocrine Society

ARTICLES

Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia

P Cohen, DM Peehl, B Baker, F Liu, RL Hintz and RG Rosenfeld
Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania.

Benign prostatic hyperplasia (BPH) is a common proliferative disorder of unknown etiology. To assess whether patients with BPH have alterations in their prostatic IGF axis, we measured the expression (by Northern blotting) and the production (by Western ligand blotting and RIA) of insulin-like growth factor-II (IGF-II) and IGF-binding proteins (IGFBPs) in prostatic epithelial and stromal cell strains grown from normal (n = 7), hyperplastic (n = 7), and malignant (n = 5) surgical specimens. Levels of IGF-II messenger ribonucleic acid (mRNA; normalized for actin expression) were 10-fold higher in BPH stromal cell strains compared to those in normal stromal cell strains (P < 0.0001). Western ligand blotting of conditioned medium (CM) from normal stromal cells demonstrated the presence of IGFBP-2, -3, and -4. In the CM of BPH stromal cells, IGFBP-2 levels were dramatically reduced to less than 20% of normal (P < 0.001). Additionally, IGFBP-5, which was not observed in significant amounts in normal stromal cell-CM, was found in large quantities in BPH stromal cell-CM. Northern blot analysis of mRNA from normal and BPH stromal cells demonstrated a 5- fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells. In prostate stromal cells from cancer specimens, no abnormalities were found. No abnormalities were observed in the IGF axis parameters evaluated in prostate epithelial cells from BPH or cancer strains. We conclude that prostatic stromal cell strains isolated from patients with BPH hyperexpress the mRNA for IGF-II and IGFBP-5 while expressing reduced amounts of IGFBP-2 mRNA. IGFBP, but not IGF-II, peptide levels in CM correspond to the mRNA differences. This is the first documentation of altered gene and protein expression in this common disease. We speculate that these abnormalities in the IGF axis may be important in the pathogenesis of BPH.

This article has been cited by other articles:

				T. L. Wadsworth, J. M. Carroll, R. A. Mallinson, C. T. Roberts Jr., and C. E. Roselli Saw Palmetto Extract Suppresses Insulin-Like Growth Factor-I Signaling and Induces Stress-Activated Protein Kinase/c-Jun N-Terminal Kinase Phosphorylation in Human Prostate Epithelial Cells Endocrinology, July 1, 2004; 145(7): 3205 - 3214. [Abstract] [Full Text] [PDF]

				T. H. Ngo, R. J. Barnard, P. Cohen, S. Freedland, C. Tran, F. deGregorio, Y. I. Elshimali, D. Heber, and W. J. Aronson Effect of Isocaloric Low-fat Diet on Human LAPC-4 Prostate Cancer Xenografts in Severe Combined Immunodeficient Mice and the Insulin-like Growth Factor Axis Clin. Cancer Res., July 1, 2003; 9(7): 2734 - 2743. [Abstract] [Full Text] [PDF]

				R. O. Roberts, D. J. Jacobson, C. J. Girman, T. Rhodes, G. G. Klee, M. M. Lieber, and S. J. Jacobsen Insulin-like Growth Factor I, Insulin-like Growth Factor Binding Protein 3, and Urologic Measures of Benign Prostatic Hyperplasia Am. J. Epidemiol., May 1, 2003; 157(9): 784 - 791. [Abstract] [Full Text] [PDF]

				S.-F. Wu, H.-Z. Sun, X.-D. Qi, and Z.-H. Tu Effect of Epristeride on the Expression of IGF-1 and TGF-{beta} Receptors in Androgen-Induced Castrated Rat Prostate Experimental Biology and Medicine, November 1, 2001; 226(10): 954 - 960. [Abstract] [Full Text] [PDF]

				S. Monti, F. Di Silverio, R. Iraci, C. Martini, S. Lanzara, P. Falasca, M. Poggi, A. Stigliano, F. Sciarra, and V. Toscano Regional Variations of Insulin-Like Growth Factor I (IGF-I), IGF-II, and Receptor Type 1 in Benign Prostatic Hyperplasia Tissue and Their Correlation with Intraprostatic Androgens J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1700 - 1706. [Abstract] [Full Text]

				S. M. Harman, E. J. Metter, M. R. Blackman, P. K. Landis, and H. B. Carter Serum Levels of Insulin-Like Growth Factor I (IGF-I), IGF-II, IGF-Binding Protein-3, and Prostate-Specific Antigen as Predictors of Clinical Prostate Cancer J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4258 - 4265. [Abstract] [Full Text]

				J. L. Martin and S. L. Pattison Insulin-Like Growth Factor Binding Protein-3 Is Regulated by Dihydrotestosterone and Stimulates Deoxyribonucleic Acid Synthesis and Cell Proliferation in LNCaP Prostate Carcinoma Cells Endocrinology, July 1, 2000; 141(7): 2401 - 2409. [Abstract] [Full Text] [PDF]

				L. Bubendorf, M. Kolmer, J. Kononen, P. Koivisto, S. Mousses, Y. Chen, E. Mahlamaki, P. Schraml, H. Moch, N. Willi, et al. Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays J Natl Cancer Inst, October 20, 1999; 91(20): 1758 - 1764. [Abstract] [Full Text] [PDF]

				A. Degeorges, F. Wang, H. F. Frierson Jr., A. Seth, L. W. K. Chung, and R. A. Sikes Human Prostate Cancer Expresses the Low Affinity Insulin-like Growth Factor Binding Protein IGFBP-rP1 Cancer Res., June 1, 1999; 59(12): 2787 - 2790. [Abstract] [Full Text] [PDF]

				C. W. Gregory, D. Kim, P. Ye, A. J. D’Ercole, T. G. Pretlow, J. L. Mohler, and F. S. French Androgen Receptor Up-Regulates Insulin-Like Growth Factor Binding Protein-5 (IGFBP-5) Expression in a Human Prostate Cancer Xenograft Endocrinology, May 1, 1999; 140(5): 2372 - 2381. [Abstract] [Full Text]

				D Danielpour Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta J. Cell Sci., January 1, 1999; 112(2): 169 - 179. [Abstract] [PDF]

				V. Hwa, C. Tomasini-Sprenger, A. López Bermejo, R. G. Rosenfeld, and S. R. Plymate Characterization of Insulin-Like Growth Factor-Binding Protein-Related Protein-1 in Prostate Cells J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4355 - 4362. [Abstract] [Full Text]

				A. M. Comaru-Schally, W. Brannan, A. V. Schally, M. Colcolough, and M. Monga Efficacy and Safety of Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix in the Treatment of Symptomatic Benign Prostatic Hyperplasia J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3826 - 3831. [Abstract] [Full Text]

				E. S. Grant, M. B. Ross, S. Ballard, A. Naylor, and F. K. Habib The Insulin-Like Growth Factor Type I Receptor Stimulates Growth and Suppresses Apoptosis in Prostatic Stromal Cells J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3252 - 3257. [Abstract] [Full Text]

				S. E. Damon, L. Maddison, J. L. Ware, and S. R. Plymate Overexpression of an Inhibitory Insulin-Like Growth Factor Binding Protein (IGFBP), IGFBP-4, Delays Onset of Prostate Tumor Formation Endocrinology, August 1, 1998; 139(8): 3456 - 3464. [Abstract] [Full Text] [PDF]

				N. Lamharzi, A. V. Schally, M. Koppan, and K. Groot Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors PNAS, July 21, 1998; 95(15): 8864 - 8868. [Abstract] [Full Text] [PDF]

				N. Boulle, A. Logié, C. Gicquel, L. Perin, and Y. Le Bouc Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tumors J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1713 - 1720. [Abstract] [Full Text]

				G. Dong, R. Rajah, T. Vu, A. R. Hoffman, R. G. Rosenfeld, C. T. Roberts Jr., D. M. Peehl, and P. Cohen Decreased Expression of Wilms' Tumor Gene WT-1 and Elevated Expression of Insulin Growth Factor-II (IGF-II) and Type 1 IGF Receptor Genes in Prostatic Stromal Cells from Patients with Benign Prostatic Hyperplasia J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2198 - 2203. [Abstract] [Full Text] [PDF]